TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease.
about
Accelerated atherosclerosis in patients with SLE--mechanisms and managementRoles of apolipoprotein E (ApoE) and inducible nitric oxide synthase (iNOS) in inflammation and apoptosis in preeclampsia pathogenesis and progressionDouble positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.Soluble TNF receptors and kidney dysfunction in the elderly.Management of cardiovascular complications in systemic lupus erythematosus.Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosusThe interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.Atherosclerosis in systemic lupus erythematosus.Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.The role of IL-1β in the bone loss during rheumatic diseases.Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases.The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus.Inflammatory rheumatic disorders and bone.SLE, atherosclerosis and cardiovascular disease.Systemic lupus erythematosus and fractures.Soluble Tumor Necrosis Factor Receptor 1 Is Associated with Glomerular Filtration Rate Progression and Incidence of Chronic Kidney Disease in Two Community-Based Cohorts of Elderly Individuals.Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.Cardiovascular risk in pediatric-onset rheumatological diseases.NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences.Systemic lupus erythematosus and cardiovascular disease.Osteoporosis and fractures in systemic lupus erythematosus.Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus.The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease.Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.Dyslipidemia in systemic lupus erythematosus.The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis.Sucrose non-fermenting AMPK related kinase/Pentraxin 3 and DNA damage axis: a gateway to cardiovascular disease in systemic lupus erythematosus among Egyptian patients.Inflammatory effects of very low-density lipoprotein and fatty acids.Lycopene reduces mortality in people with systemic lupus erythematosus: A pilot study based on the third national health and nutrition examination survey.Premature coronary heart disease in SLE: can we prevent progression?Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease.Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.Natural antibodies against phosphorylcholine as potential protective factors in SLE.Inflammation and Trajectory of Renal Function in Community-Dwelling Older Adults.Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus.Inflammatory diseases and bone fragility.The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity.
P2860
Q26820245-E9804C91-5707-4586-B08C-AB359F83B598Q28395226-7B446C80-209B-41AB-87E5-DAF59DD20529Q31136769-C85BDEAE-67C3-450D-A473-B6FE296544FCQ33387473-222A5D39-FD29-49CD-86CA-54809A017F2CQ33660677-C23DF8CB-0D53-4209-8371-024CE940459DQ33730536-D28D59AD-2C96-4B6C-9291-A308D90833B5Q34170097-7DDC9E77-3353-42D2-A8B3-5CF8DAE56462Q34613997-018ABB62-0A5B-4754-9F9B-8DE8C951490FQ35169351-45FA3FD5-326B-423B-9EB2-307F59E3AD5FQ35525108-310B54F3-8788-412C-A386-73F15D4E587AQ35539166-ECE8D880-7016-403E-AD18-08BE292F9984Q35540844-7CE49D77-DEC7-487B-90B4-3725C56351E5Q35614331-1B996C9D-D51A-4F3E-9653-E8EADFB0C577Q35867539-9B44BE40-1F0A-4DFE-BA07-0C9730FE9960Q35918747-5CF27CBD-D643-4814-97CD-9C26A045E7CDQ36135534-B2D2762A-7ECC-49C6-B7B8-8AE365746230Q36246074-F7C1E527-499F-4433-9FA2-CEEF5A02501EQ36325841-FD11DF7E-59F4-473C-ABF6-AA6040F986ECQ36611056-70E06A39-FF89-40DF-8084-9B937083FF7AQ36903089-51A1604A-7A93-45D6-BD02-DDE72C63E154Q37153919-55758987-23B4-4C49-8E37-0F49D011B0E8Q37167995-0261FC3E-07A3-468C-A01A-CA3BA250624CQ37972874-46F31C8A-39D7-419F-A156-77439A379E01Q38162490-4757EF4A-A116-4B0F-A035-19D31F84B87CQ38185266-9C49CE47-D831-4A86-8AD0-DC108DE71394Q39101016-D5248648-490A-48FC-B51C-897FA36173CBQ39123611-AA3D35E3-16F4-40A9-AEB4-5A8861CEB418Q39400939-37BBD352-21A5-4D07-93DB-E80987684C85Q39632598-7804436B-E9D5-4C04-943A-D5A5461522E2Q40329911-EF4253E1-E47D-45B2-AC34-6E1D903932A7Q40980519-277FDF21-EB5B-4C0B-96EA-6FA2A37B7D09Q43900414-85A0980A-F8EE-4914-BAB2-15028C33E931Q44112580-54321365-3852-4D4F-9F84-E7055244CA72Q44586795-6654D070-601C-45FD-90E8-40EB3FB5429CQ45085322-87ED7FE1-DC9B-4A58-A17F-B53457DFAB47Q46560299-FD4E30FA-1FE7-41F7-930D-46E34C2D1CA8Q47557606-CB47A4BC-5129-4A3B-A1A4-8056C315705FQ47952057-C6969611-2649-4F25-858B-868A158F8A19Q47975714-D76C33A3-1868-4B53-B3C8-8B51B0C017B2Q50417164-1BDC91E5-3593-4910-8C59-439C9AA81B3C
P2860
TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@en
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@nl
type
label
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@en
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@nl
prefLabel
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@en
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@nl
P2860
P50
P921
P1433
P1476
TNF-alpha: a link between hype ...... s with cardiovascular disease.
@en
P2093
K Jensen-Urstad
P2860
P304
P356
10.1191/0961203303LU412OA
P577
2003-01-01T00:00:00Z